Casma Therapeutics
Steven Gygi joined the department of cell biology at Harvard Medical School in 2000 and has since spent nearly two decades exploring the growing field of mass spectrometry-based proteomics. His lab conducts comprehensive measurements of protein properties using mass spectrometry technology. The results allow for a wide-ranging analysis of biological responses to environmental, genetic, and pharmacological perturbations. In addition to his work at Harvard Medical School, Steven is a member of the scientific advisory board at Thermo Fisher Scientific and a scientific co-founder of Cedilla Therapeutics. He earned his Ph.D. in pharmacology and toxicology from the University of Utah and conducted postdoctoral research with Professor Ruedi Aebersold, an early trailblazer in the proteomics field, at the University of Washington.
This person is not in the org chart
This person is not in any offices
Casma Therapeutics
Casma Therapeutics harnessing the natural process of autophagy to design powerful new medicines for a broad range of diseases.